Keros Therapeutics swings to Q3 net income of $14.15 million
KROS•Keros Therapeutics reported third-quarter 2026 net income of $14.15 million, primarily due to revenue recognized under its Takeda license agreement. Revenue more than doubled year over year to $40.01 million, and the company had $259.46 million in cash and cash equivalents at September 30.
1. Quarterly results
Keros Therapeutics swung to third-quarter 2026 net income of $14.15 million, primarily due to revenue recognized under its Takeda license agreement. Revenue more than doubled year over year to $40.01 million.
2. Cash and trial update
Cash and cash equivalents totaled $259.46 million at September 30, with funding expected to last into the second half of 2028. The Phase 2 rinvatercept DMD trial dosed its first patient in September 2026, and initial data are expected in the first half of 2027.
